Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nach dem Genius Act: Dieses börsennotierte XRP-Unternehmen greift im Token-Finanzmarkt an!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
161 Leser
Artikel bewerten:
(0)

Endoscopic Retrograde Cholangiopancreatography Market To Hit $2,557.7 Million by 2030, says P&S Intelligence

NEW YORK, June 14, 2022 /PRNewswire/ -- In 2021, the global endoscopic retrograde cholangiopancreatography market produced $1,270.9 million, which is on the path to hitting $2,557.7 million by 2030, witnessing a compound average growth rate of 8.1% between 2021 and 2030. This is owing to the paradigm shift toward less-invasive diagnostic techniques and growth in the incident of pancreatic cancer.

P_and_S_Intelligence_Logo

Furthermore, in certain countries, the presence of health coverage is fueling the market expansion. For example, in the U.S., an average endoscopy costs more than $3,000, but with health insurance, the cost may reduce by up to $1,500.

Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/endoscopic-retrograde-cholangiopancreatography-ercp-market/report-sample

North American Market Driven by Rising Prevalence of Pancreatic Cancer

The North American ERCP market generated $471.4 million revenue in 2021. Alcohol usage is increasing, which is contributing to the rising incidence of disorders including pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Furthermore, over 20% of the population of Canada lives with bile duct illnesses.

Additionally, the FDA's approval to numerous ERCP devices has accelerated the market expansion. For example, Ambu Inc. obtained the FDA certification for the Ambu aScope Duodeno, a sterile, single-use duodenoscope, in July 2020.

APAC Region Is Predicted To Grow at a Significant CAGR

During the projection period, the APAC endoscopic retrograde cholangiopancreatography market is predicted to advance at the highest CAGR, of 8.5%. This will be due to the rise in the patient knowledge of ERCP devices, as well as in the incidence of pancreatic cancer and GERD. Furthermore, the increasing number of awareness campaigns and government initiatives aimed at bile duct cancer, pancreatic diseases, and related issues are likely to drive ERCP device demand in the region. Furthermore, in 2021, China and Japan together accounted for almost 60% of the regional market revenue.

Browse detailed report on ERCP Market Evolving Technology and Growth Outlook 2022 to 2030

ERCP Market Segmentation Analysis

  • In 2021, the endotherapy devices category accounted for around 40% share in the market. This was due to the rise in the demand for ERCP devices, as well as the high prevalence of pancreatitis, gallstones, choledocholithiasis, and pancreatic cancer.
  • Due to the surge in the occurrence of chronic biliary and gastrointestinal illnesses, endoscopes accounted for over 30% share in 2021. Moreover, companies are working hard to introduce a variety of endoscopes, which is creating lucrative prospects for the field.
  • In 2021, the biliary sphincterotomy category held a roughly 45% revenue share in the endoscopic retrograde cholangiopancreatography market. This is because ERCP devices are commonly used to treat bile blockage and bile duct stones and to perform cell sampling and stent implantation.
  • The most-common end users of ERCP are hospitals and clinics, and this category is predicted to grow at a CAGR of roughly 8.3% in the future. This may be attributed to the rise in the count of trained and accredited endoscopists, including gastroenterologists and surgeons, as well as the growth in the number of hospitals.

Browse More Related Reports

Global Medical Equipment Maintenance Market Research Report with Top Players and Growth Opportunity

Global Medical Robotic Systems Market Research Report with Top Players and Growth Opportunity

Global Endoscope Market Research Report with Top Players and Growth Opportunity

About P&S Intelligence

P&S Intelligence provides market research and consulting services to a vast array of industries across the world. As an enterprising research and consulting company, P&S believes in providing thorough insights on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness. P&S keeps the interest of its clients at heart, which is why the insights we provide are both honest and accurate. Our long list of satisfied clients includes entry-level firms as well as multi-million-dollar businesses and government agencies.

Contact:
Prajneesh Kumar
P&S Intelligence
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Follow Us: LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/1224988/P_and_S_Intelligence_Logo.jpg

© 2022 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.